<div id="readability-page-1"><p>Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.</p><div><p><span></span><span>Get <strong>Maze Therapeutics</strong> alerts:</span></p></div><ul><li>Biotech Breakouts: 3 Stocks With Massive Upside Potential</li></ul><p>Amy Bachrodt also recently made the following trade(s): </p><ul><li>On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $45.52, for a total value of $227,600.00. </li><li>On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $39.15, for a total value of $195,750.00. </li><li>On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total value of $405,800.00. </li><li>On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total value of $200,400.00. </li></ul><h2>Maze Therapeutics Stock Up 0.4%</h2><p>Shares of MAZE traded up $0.17 during trading hours on Wednesday, hitting $48.14. 588,235 shares of the company were exchanged, compared to its average volume of 434,867. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $48.94. The company has a market cap of $2.32 billion and a price-to-earnings ratio of -2.30. The firm's fifty day moving average is $41.28 and its 200 day moving average is $29.58. </p><p>Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.08. </p><h2>Institutional Investors Weigh In On Maze Therapeutics</h2><p>Several hedge funds have recently modified their holdings of MAZE. CWM LLC acquired a new position in  Maze Therapeutics in the 2nd quarter worth about $28,000.  GF Fund Management CO. LTD. bought a new stake in shares of  Maze Therapeutics during the fourth quarter worth about $39,000.  Ameritas Investment Partners Inc. grew its holdings in shares of  Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after purchasing an additional 738 shares during the last quarter.  Russell Investments Group Ltd. increased its stake in shares of  Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after buying an additional 1,725 shares during the period.  Finally, China Universal Asset Management Co. Ltd. bought a new position in  Maze Therapeutics in the 3rd quarter valued at approximately $52,000. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several analysts recently issued reports on MAZE shares. Wall Street Zen upgraded shares of Maze Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, January 25th. Weiss Ratings  restated a &#34;sell (d)&#34; rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. BTIG Research raised their target price on Maze Therapeutics from $37.00 to $46.00 and gave the company a &#34;buy&#34; rating in a report on Friday, January 16th. Guggenheim  reissued a &#34;buy&#34; rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Friday, December 19th. Finally, Wells Fargo &amp; Company initiated coverage on Maze Therapeutics in a research note on Thursday, December 4th. They issued an &#34;overweight&#34; rating and a $55.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued  a Buy rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, Maze Therapeutics presently has an average rating of &#34;Buy&#34; and an average price target of $44.50.</p><p><b>Get Our Latest Analysis on MAZE</b></p><h2>Maze Therapeutics Company Profile</h2> (Get Free Report)<p>Maze Therapeutics, Inc <span>NASDAQ: MAZE<span></span></span> is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.  </p><p>Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Maze Therapeutics</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>The gold chart Wall Street is terrified of…</li><li>BREAKING: Elon Makes a Quiet Shift That Changes Everything</li><li>GOLD ALERT</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUFaRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUFaRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Maze Therapeutics Right Now?</h2><p>Before you consider Maze Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.</p><p>While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MAZE

<p>Amy Bachrodt, SVP of Maze Therapeutics (NASDAQ:MAZE), sold 5,000 shares at $46.04 each on February 2nd, totaling $230,200. This sale reduced her ownership by 27.83%, leaving her with 12,965 shares valued at approximately $596,908.60. The transaction was disclosed to the SEC. Maze Therapeutics' stock rose 0.4% to $48.14, with a market cap of $2.32 billion. Analysts have mixed ratings on the stock, with an average target price of $44.50.</p>

Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock